- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
LexaGene Holdings announced it had closed its offering, which totaled 12.7 million units at C$0.52 each for gross proceeds of C$6.64 million.
LexaGene Holdings (TSXV:LXG, OTCQB:LXXGF) has announced it has closed its previously announced offering of units for gross proceeds of C$6.6 million.
As quoted in the press release:
The Company issued 12,769,626 Units at a price of CAD$0.52 per Unit, each Unit consisting of one common share of the Company (a “Share”) and one common share purchase warrant, with each warrant entitling the holder to purchase one Share at the price of CAD$0.75 per Share until October 29, 2022.
The Offering was conducted by Industrial Alliance Securities Inc. (the “Agent”). The Company issued to the Agent an aggregate of 735,229 broker warrants (the “Broker Warrants”), each Broker Warrant entitling the holder to purchase one Share at the price of CAD$0.52 per Share until October 29, 2022.
Dr. Jack Regan, CEO and Founder of LexaGene states, “We would like to thank our current shareholders for their continued support and we welcome our new retail and institutional shareholders to LexaGene with this raise, our largest to date. This raise solidifies our pathway to commercialization in 2020 and marks a very exciting time for LexaGene.”
The Company intends to use the net proceeds of the Offering for research and development, marketing, general corporate purposes to support commercialization efforts.
This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “1933 Act”), or any state securities laws, and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.